France Cancer Immunotherapy Market Analysis

France Cancer Immunotherapy Market Executive Analysis

France's cancer immunotherapy market is at around $3.09 Bn in 2022 and is projected to reach $4.96 Bn in 2030, exhibiting a CAGR of 6.1% during the forecast period. The French government set the national health insurance budget at 2.7 % of GDP, an increase of $5 Bn from the previous year. The funds will be used to modernize the healthcare system, which will enhance local healthcare delivery and the standard of treatment offered by public institutions. Due to a decrease in the amount of cash required for COVID-related care, the social security spending deficit will drop from $19 Bn to $7.45 Bn in 2023.

In France, cancer is a significant public health issue due to its high prevalence. Over 400,000 new instances of cancer were reported in France in 2018, making it the main cause of death there, according to the French National Cancer Institute (INCa). Breast cancer, lung cancer, colorectal cancer, prostate cancer, and skin cancer are the most prevalent cancers in France. Due to anti-smoking programs, the incidence of some cancers, such as lung cancer, has decreased recently, but the incidence of other cancers, such as skin cancer, has increased.

Over the past ten years, immunotherapy medications, which train the immune system to recognize and eliminate malignant cells, have shown tremendous promise against tumors that were previously incurable. According to the director of clinical research at France's Curie Institute, a major area of research currently focuses on raising the proportion of patients who respond favourably to immunotherapy. Additionally, research is being done on immunotherapy, which is used in conjunction with chemotherapy to target cancer cells that have undergone mutations that may make them simpler for the immune system to detect and destroy. Checkpoint inhibitor therapy is an additional strategy that has demonstrated promise. Cancer-related proteins can connect to immune cells and tell the rest of the immune system to turn off, weakening the body's defenses. By effectively blocking this binding, checkpoint inhibitor medication enables killer immune T-cells to locate and eliminate the infection. For some melanomas and lung malignancies, this method has already dramatically improved prognoses, and additional trials are currently being conducted.

Market Dynamics

Market Growth Drivers

Over 400,000 new cases of cancer are reported each year in France, making it a significant public health concern. The demand for novel medicines, such as cancer immunotherapy, is being driven by the increase in the prevalence of cancer. The France cancer immunotherapy market is expanding, which is also a result of France's ageing population. Older persons have a higher risk of getting cancer and can need more aggressive therapies. New and more potent cancer immunotherapies have been created as a result of recent technological advances. With less harm to healthy cells, these new medicines are better suited to target cancer cells. Patients and medical professionals are becoming more aware of the advantages of cancer immunotherapy. The demand for these therapies is rising as a result of the increasing awareness, which is also fueling the France cancer immunotherapy market's expansion.

Market Restraints

The high cost of cancer immunotherapy therapies may prevent some patients from receiving them. Cost factors may influence the use of these medicines in France since healthcare is mostly paid for by the public. Cancer immunotherapies have demonstrated favourable outcomes in some cancer types, but they may be less successful in others. This reduces the France cancer immunotherapy market potential and could delay adoption. While the development and commercialization of cancer immunotherapies are generally encouraged in France, there are still regulatory obstacles that could delay their uptake. For instance, getting paid for these therapies can be a difficult and drawn-out process.

Competitive Landscape

Key Players

• Cellectis (FRA)- It is developing Universal CARTs (UCARTs), a unique form of CART therapy
• ImCheck (FRA)- This French firm creates cancer-fighting antibody medicines. ImCheck, a company based in Marseille, has created a pipeline of monoclonal antibodies that target particular members of the butyrophilin (BTN) family of checkpoint molecules, which activate gamma delta T cells. Gamma delta T cells are innate immune cells that normally combat cancer cells
• Biomunex Pharmaceuticals (FRA)
• Transgene (FRA)
• AstraZeneca
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Pfizer
• Eli Lily
• Novartis

Healthcare Policies and Regulatory Landscape

The majority of healthcare expenses are covered by the government in France, where healthcare is mostly publicly subsidized. The Assurance Maladie national health insurance program provides a variety of medical services, including cancer treatment. In France, public hospitals that are fully sponsored by the government are mainly used to treat cancer patients. The French National Cancer Institute (INCa), which has created criteria for the reimbursement of cancer medications and therapies, maintains a policy of reimbursement for cancer treatment. The guidelines consider both the treatment's cost-effectiveness and the clinical benefit it offers to patients. The French national health insurance system will pay for cancer medications and therapies that have been authorized by the National Agency for Medicines and Health Products Safety (ANSM). However, because of the intricate and drawn-out process of analyzing their cost-effectiveness and therapeutic efficacy, there are frequent delays in receiving payment for newer, cutting-edge cancer treatments.